Newsroom

The new guideline comes as FDA weighs an advisory panel recommendation for CGM dosing, which many see as a first step toward Medicare coverage.
Analysis of prescription transaction data provided insight into reduced out-of-pocket spending and increased medical fill rates for people who gained coverage under the Affordable Care Act and had at least 1 chronic condition.
A new study by researchers at the Perelman School of Medicine has identified a predictive biomarker in stage IV patients with melanoma being treated with the pembrolizumab.
A series of papers in The Lancet highlights how city planning and urban design can prevent chronic diseases and create healthier and more sustainable cities.
Access to, and levels of spending on, prescription drugs has become an important public policy issue. The development and implementation of patient-centered solutions that allow access to medications at an affordable cost are of critical importance.
The American Association for the Study of Liver Diseases/Infectious Diseases Society of America Guidance Panel is recommending that before patients begin antiviral therapies for the treatment of hepatitis C, that they be screened for hepatitis B, as well.
What we're reading, September 26, 2016: the obesity rate in America has been rising steadily, but the health system is ill equipped to treat these patients; the pros and cons of mail-order medications; and barring recipients of federal funding from preventing money from going to Planned Parenthood.
AbbVie’s blockbuster arthritis medication, adalimumab (Humira), now has an FDA-approved competitor: Amgen’s adalimumab-atto, also called Amjevita.
Compendia
Diabetes Compendium
HCV Compendium
Oncology Compendium
Reimbursement Compendium
Know Your News
HF Compendium
$AD300x250BB$
$vacMongoViewPlus$